The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1421
Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved crofelemer (kroe fel’ e mer; Fulyzaq – Salix), a chloride channel inhibitor derived from the red sap of the South American plant Croton lechleri, for symptomatic relief of noninfectious diarrhea in patients with HIV taking antiretroviral drugs. It is the first drug approved for relief of antiretroviral-induced diarrhea and the first oral botanical drug approved by the FDA.

MECHANISM OF ACTION — Diarrhea is a common adverse effect of antiretroviral therapy. Crofelemer inhibits the secretion of chloride ions into the intestinal lumen by inhibiting both cystic fibrosis transmembrane conductance regulator and calcium-activated chloride channels. As a result, less water is drawn into the intestinal lumen via osmosis. Systemic absorption of crofelemer is minimal.1,2

A CLINICAL STUDY — Approval of crofelemer was based on ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Crofelemer (Fulyzaq) for Antiretroviral-Induced Diarrhea
Article code: 1421c
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian